Lyra Therapeutics (LYRA) Asset Writedowns and Impairment (2023 - 2024)
Lyra Therapeutics (LYRA) recorded quarterly Asset Writedowns and Impairment of $1.7 million in Q4 2024, down 7.43% on a QoQ basis from $1.9 million in Q2 2024, and up 21687.5% YoY from N/an in Q1 2024.
Lyra Therapeutics (LYRA) Asset Writedowns and Impairment (2023 - 2024) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Asset Writedowns and Impairment for 2 consecutive years, with $1.7 million the latest figure, recorded in Q4 2024.
- Asset Writedowns and Impairment for Q4 2024 came in at $1.7 million, up 21687.5% year-over-year; the trailing twelve-month figure through Sep 2025 was $1.7 million (down 7.83% YoY), and the FY2024 annual result was $1.9 million, up 17.69% from the prior year.
- Asset Writedowns and Impairment for Q4 2024 stood at $1.7 million, down from $1.9 million in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $1.9 million in Q2 2024, with the low at $8000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.74 Mn |
| Dec 31, 2024 | 1.74 Mn |
| Jun 30, 2024 | 1.88 Mn |
| Jun 30, 2024 | 1.88 Mn |
| Dec 31, 2023 | 8,000.00 |
| Dec 31, 2023 | 8,000.00 |
| Jun 30, 2023 | 1.59 Mn |
| Jun 30, 2023 | 1.59 Mn |